| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2017: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2016: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2014: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2013: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Outline of Final Research Achievements |
60 patients with advanced stage solid tumor were included. Iron chelate Tx was administered to patients diagnosed with iron overload after transfusion since April 2011. Changes in ferritin levels after transplantation in non-administered and administered groups were compared and examined. Forty patients (10 non-treated group, 30 treated group) satisfied the criteria for iron overload after transfusion. The treatment group passed without any serious adverse events, the ferritin value became less than 500 ng / ml on 65 days (35-180) after transplantation and administration was discontinued. Ferritin levels in the non-administered group were significantly higher than 1210 ng / ml (810-2557) vs 230 ng / ml (120 - 1220) (p = 0.016) in the transplanted 1 year
Serum ferritin in the non-administered group was still high (1108 ng / ml (421-2202)). It was suggested that early iron chelate Tx administration for iron overload disease leads to reduction of organ damage.
|
